Physician profile
David Matthew Schwartzberg
NPI 1336439686
$26,212.77
in general payments reported to CMS, 2019-2025
14 companies · $688 in 2025
The $688 reported for 2025 was more than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $188 · 2021: $7,337 · 2022: $638 · 2023: $238 · 2024: $17K · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Travel and Lodging: $1,096 · Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,065.00 |
| Travel and Lodging | $1,096.36 |
| Food and Beverage | $776.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $17,773.99 | 2023-2025 | |
| Intuitive Surgical, INC. | $7,542.51 | 2021-2022 | |
| Janssen Biotech, INC. | $186.06 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Medtronic, INC. | $147.88 | 2021 | |
| Axonics, INC. | $145.64 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.20 | 2022-2025 | Xifaxan, Plenvu |
| Ethicon US, LLC | $65.01 | 2022-2025 | Endopath |
| Coloplast Corp | $45.39 | 2020 | |
| Abbvie INC. | $45.13 | 2020 | |
| Davol INC. | $43.28 | 2021 | |
| Smith+Nephew, INC. | $42.31 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.81 | 2020-2023 | Gattex |
| Lilly USA, LLC | $28.23 | 2023 | |
| Braintree Laboratories, INC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schwartzberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.